This protocol permits the evaluation and treatment of subjects with hereditary and acquired hemolytic diseases, to facilitate understanding of pathogenesis and natural history vaso-occlusive painful crisis and pulmonary complications of sickle cell disease and related cardiopulmonary complications of other hereditary, acquired and iatrogenic hemolytic disorders. Patients are evaluated with a medical history and physical examination and routine laboratory studies are obtained as needed to assess diagnosis, disease activity, and disease, and disease complications and to monitor for treatment-related responses and toxicities. Blood is obtained, with subject?s consent, for research studies evaluating gene/protein expression and to evaluate the role of vasodilators, vasoconstrictors, inflammatory and redox stress mediators in this population. Patients identified with pulmonary hypertension have the option to undergo invasive hemodynamic evaluation and treatment with Food and Drug Administration (FDA) approved drugs, according to current standards of medical practice, with signed informed consent for all offered procedures. Patients eligible for other research protocols are offered the opportunity to participate in these studies by signed informed consent. Apart from such protocols, any medical care recommended or provided to the patients are consistent with routine standards of practice and are provided in consultation with the patient?s referring physician. The study provides a means to evaluate and treat patients, and to generate hypotheses and protocols based on this clinical experience in sickle cell disease and in other acquired or inherited hemolytic anemias. This study began enrolling subjects in April 2004 and we currently have enrolled 136 patients. This study allows us to continue to gather knowledge and clinical experience to facilitate the understanding of the natural history of cardiopulmonary complications of sickle cell disease and other hemolytic disorders.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL008070-03
Application #
7332497
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2006
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Castro, Mario; Ramirez, Maria I; Gern, James E et al. (2009) Strategic plan for pediatric respiratory diseases research: an NHLBI working group report. Proc Am Thorac Soc 6:1-10
Abman, Steve; Jobe, Alan; Chernick, Victor et al. (2009) Strategic plan for pediatric respiratory diseases research: an NHLBI working group report. Pediatr Pulmonol 44:2-13
Olnes, Matthew; Chi, Amy; Haney, Carissa et al. (2009) Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. Am J Hematol 84:530-32
Strouse, John J; Takemoto, Clifford M; Keefer, Jeffrey R et al. (2008) Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer 50:1006-12
Darbari, Deepika S; Castro, Oswaldo; Taylor 6th, James G et al. (2008) Severe vaso-occlusive episodes associated with use of systemic corticosteroids in patients with sickle cell disease. J Natl Med Assoc 100:948-51
Taylor 6th, James G; Woods, Gerald M; Machado, Roberto et al. (2008) Severe pulmonary hypertension in an adolescent with sickle cell disease. Am J Hematol 83:71-2
Kato, Gregory J; Gladwin, Mark T (2008) Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 300:2638-46
Kato, Gregory J; Onyekwere, Onyinye C; Gladwin, Mark T (2007) Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr Hematol Oncol 24:159-70
Kato, Gregory J; McGowan, Vicki; Machado, Roberto F et al. (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107:2279-85
Little, Jane A; McGowan, Vicki R; Kato, Gregory J et al. (2006) Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica 91:1076-83

Showing the most recent 10 out of 18 publications